GE HealthCare Technologies Inc. reported first‑quarter 2026 results on April 29, 2026, with revenue of $5.13 billion, a 7.4% year‑over‑year increase that beat the consensus estimate of $5.05 billion. Adjusted earnings per share came in at $0.99, missing the consensus estimate of $1.07 by $0.08 and the lower estimate of $1.05 by $0.06. The company’s adjusted EBIT margin contracted to 13.5% from 15.0% in the prior year, prompting a trim of the full‑year 2026 adjusted EPS guidance to $4.80‑$5.00 from $4.95‑$5.15 and a revised adjusted EBIT margin outlook of 15.1%‑15.4%.
Revenue growth was driven by strong performance in Pharmaceutical Diagnostics, Advanced Visualization Solutions, and Imaging, while the Patient Care Solutions segment experienced an organic decline. The company closed the quarter with a record backlog of $21.8 billion, up $1.2 billion year‑over‑year, and reported a 2.9% organic revenue increase. China market revenue declined year‑over‑year but improved sequentially, aligning with expectations. The company’s strategic evolution created a new Advanced Imaging Solutions segment by merging Imaging and Ultrasound units, and it completed a $2.3 billion acquisition of Intelerad, expected to be slightly dilutive in 2026 but accretive in 2027.
"Profitability in the first quarter was impacted by a PDx supplier issue that has since been resolved. We saw significant increases in memory chips, oil and freight costs during the first quarter that we assume will impact the rest of 2026. Given these dynamics, we are taking a prudent approach and reducing our profit outlook but expect to offset more than half of the inflation impact with price and cost actions." – Peter Arduini, President and CEO. "We delivered a solid book to bill at 1.07 times, and we exited the quarter with a record backlog of $21.8 billion, up $1.2 billion year‑over‑year. We were disappointed with the adjusted EBIT margin of 13.5% and adjusted EPS of $0.99." – James S. Saccaro, CFO. "We expect to offset more than half of the inflation impact in 2026 with price and cost actions. Taking a prudent view for the year, we are reducing our full year adjusted EPS guidance by $0.15 associated with the remaining inflation impact. Including this impact, we will still deliver mid‑ to high‑single digit adjusted EPS growth." – James S. Saccaro, CFO. "As we start the year, we're pleased with topline performance, which came in at the high end of our expectations. Growth was driven by strong commercial execution in Pharmaceutical Diagnostics, including Flyrcado, Advanced Visualization Solutions, and Imaging, as well as services. We are maintaining our topline growth guidance driven by healthy customer demand globally." – Peter Arduini, President and CEO. "Importantly, we are making meaningful progress executing on our new wave of innovation to accelerate future revenue and margin growth." – Peter Arduini, President and CEO.
The company’s guidance cut signals a cautious stance amid macro‑economic headwinds, with investors reacting negatively to the margin compression and the downward revision of profit outlook. The EPS miss and tighter guidance underscore the impact of rising input costs—particularly memory chips, oil, and freight—estimated at $250 million for 2026, and the lingering effects of tariff exposure, of which the company has already neutralized over 50% of its 2025 exposure.
Investors are likely to reassess the company’s near‑term profitability outlook, weighing the company’s strong backlog and ongoing innovation against the headwinds of cost inflation and tariff uncertainty. The guidance cut and margin contraction suggest that management expects to manage inflationary pressures through price and cost actions, but the revised outlook indicates that these measures may not fully offset the rising costs in the short term. Long‑term prospects remain supported by the record backlog and the strategic integration of Intelerad and the new Advanced Imaging Solutions segment, which are expected to enhance revenue and margin growth over the next few years.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.